Pfizer Inc.

Pfizer Inc.

PFE·NYSE

$25.36

-1.1%
HealthcareDrug Manufacturers - General

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$144.51B
EPS1.3600
P/E Ratio18.64
Earnings Date08/04/2026

pfe

Effect of Foreign Exchange Changes on Cash

Last Annual Value

49.00M

3-Year CAGR

32%

5-Year CAGR

52%

10-Year CAGR

7%

Pfizer Inc.

Pfizer Inc. Competitors Analysis of Effect of Foreign Exchange Changes on Cash

PFE · NYSE
CompanyEffect of Foreign Exchange Changes on Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
PFE logo
Pfizer Inc.
NYSE:PFE
49.00M
N/AN/AN/A 
AMGN logo
Amgen Inc.
NASDAQ:AMGN
0.00
N/AN/AN/A
563.00M
190.4%N/AN/A
187.00M
60.8%N/AN/A
68.00M
N/AN/AN/A
278.00M
67.6%N/AN/A
92.00M
17.3%N/A8.4%
42.00M
N/AN/AN/A
Pfizer Inc.

Pfizer Inc. Fair Value Envelope

PFE · NYSE

Our analysis suggests that PFE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $25.355, this represents a potential HIDDEN relative to our calculated worth for Pfizer Inc..

Intrinsic Value
Current Price: $25.355